ARBは糖尿病患者の心不全を予防するが心疾患全般はカルシウム拮抗薬と差がない

median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio: 0.97 [95% CI: 0.66-1.40]; P=0.85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio: 0.20 [95% CI: 0.06-0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan- and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group. 一般にアンジオテンシンII受容体拮抗薬（ARB)がカルシウム拮抗薬より糖尿病患者にはいいと思われているが1150名にランダムに割り付けてみたら心疾患一般については差がなかった。しかしARBのバルサルタンの方が心不全が少ないという結果だった。
Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study; Muramatsu T, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, Ichimiya S, Ohno M, Sone T, Ikeda N, Watarai M, Murohara T, for the NAGOYA HEART Study Investigators; Hypertension (Jan 2012)